CPL423 showed high permeability, metabolic stability, and low cardiovascular liability.<h4>Discussion</h4>CPL423 provides direct antitumor activity via dual TAM/FLT3 inhibition and immune-mediated effects on antigen-presenting cells, addressing resistance mechanisms in AML and TAM/AXL-driven solid tumors and supporting further development, including combination regimens. This evidence concerns the gene FLT3 and acute myeloid leukemia.